Video

Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma

Author(s):

Erica Bell, PhD
Conference|ASCO Annual Meeting

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Related Content
FDA
October 24th 2024

FDA Grants Priority Review to TLX101-CDx for Glioma Imaging

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
May 10th 2021

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

Randall B. Riggs, MBA
October 11th 2024

FDA Grants Orphan Drug Designation to LMP744 for Glioma

MTX110 in Recurrent Glioblastoma | Image Credit: © Dr_Microbe - stock.adobe.com
October 4th 2024

MAGIC-G1 Study Provides Updated Findings With MTX110 in Recurrent Glioblastoma

Panna Sharma
September 24th 2024

LP-184 Earns 3 FDA Rare Pediatric Disease Designations Across Ultra-Rare Tumor Types

William Ho, chief executive officer and co-founder of IN8bio,
September 11th 2024

Clinical Development of Gamma-Delta T-Cell Therapy INB-400 Paused in Glioblastoma